Corvia Medical

Executive Summary

Corvia Medical is a private US-based medical device company pioneering interventional therapies for heart failure through its Corvia Atrial Shunt, a minimally invasive implant designed to reduce left atrial pressure. The company aims to alleviate symptoms, reduce hospitalizations, and improve quality of life for heart failure patients, addressing a significant unmet need in cardiovascular medicine. Founded in 2009, Corvia has advanced its technology through global clinical trials, with the REDUCE LAP-HF program being its most prominent. The company operates in a competitive landscape but offers a unique mechanical solution distinct from pharmacologic approaches. Despite past mixed trial results, Corvia continues to refine patient selection and device design, positioning itself for potential regulatory milestones and commercial validation.

Upcoming Catalysts (preview)

• Q3 2026REDUCE LAP-HF II Trial Top-Line Results60% success
• Q4 2026FDA Premarket Approval (PMA) Submission50% success
• Q2 2026Strategic Partnership or Licensing Agreement70% success